Jul 30, 2026 08:05AM

Jul 30, 2026 08:05AM

Jun 30, 2026 07:30AM

Jun 12, 2026 04:05PM

Jun 8, 2026 04:05PM

Jun 8, 2026 04:05PM

May 27, 2026 04:05PM Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference

May 12, 2026 04:05PM

May 11, 2026 04:05PM

Apr 17, 2026 04:05PM

Apr 15, 2026 04:05PM

Apr 15, 2026 04:05PM

Apr 7, 2026 08:08AM

Apr 7, 2026 08:05AM Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis

Mar 31, 2026 04:27AM

Mar 30, 2026 08:05AM

Mar 30, 2026 08:05AM

Mar 16, 2026 11:22AM

Mar 13, 2026 08:06AM

Mar 13, 2026 08:05AM

Mar 6, 2026 04:05PM Savara receives FDA day 74 letter, submits European filing for MOLBREEVI

Mar 6, 2026 04:05PM

Mar 4, 2026 04:05PM

Feb 23, 2026 04:58AM

Feb 20, 2026 04:15PM

Feb 20, 2026 04:15PM

Feb 13, 2026 04:05PM

Feb 4, 2026 04:05PM Savara Announces Participation in Upcoming Investor Healthcare Conferences

Jan 27, 2026 08:06AM

Jan 27, 2026 08:05AM

Jan 16, 2026 04:05PM

Jan 8, 2026 04:05PM

Dec 23, 2025 06:46AM

Dec 22, 2025 08:31AM

Dec 22, 2025 08:30AM Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimm

Dec 17, 2025 08:05AM

Dec 11, 2025 08:05AM

Dec 11, 2025 08:05AM

Dec 2, 2025 08:06AM

Dec 2, 2025 08:05AM

Nov 20, 2025 04:05PM

Nov 12, 2025 04:05PM Savara Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 3, 2025 04:05PM

Oct 31, 2025 04:05PM

Oct 31, 2025 04:05PM

Oct 29, 2025 09:43PM

Oct 29, 2025 09:43PM

Oct 29, 2025 04:07PM

Oct 29, 2025 04:07PM Savara Announces Proposed Public Offering

Oct 29, 2025 04:01PM

327,060 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All